AIM CLINICAL APPROPRIATENESS GUIDELINES FOR GENETIC TESTING
The foundation of our solution platform for specialty benefits management is our clinical appropriateness guidelines. AIM Clinical Appropriateness Guidelines for Genetic Testing are developed through a rigorous process integrating evidence-based literature with expert review.
AIM CLINICAL APPROPRIATENESS GUIDELINES FOR GENETIC TESTING FOR HEREDITARY CARDIAC DISEASE
The testing addressed in the AIM Clinical Appropriateness Guidelines for Genetic Testing for Hereditary Cardiac Disease includes testing for inherited arrhythmias and cardiomyopathies.
COMING SOON GUIDELINES EFFECTIVE AS OF MARCH 3, 2020*
* GUIDELINES EFFECTIVE AS OF MARCH 4, 2020 FOR PREMERA BLUE CROSS AND LIFEWISE MEMBERS
AIM CLINICAL APPROPRIATENESS GUIDELINES FOR GENETIC TESTING FOR HEREDITARY CANCER SUSCEPTIBILITY
The testing addressed in the AIM Clinical Appropriateness Guidelines for Genetic Testing for Hereditary Cancer Susceptibility includes screening for hereditary cancer predisposition syndromes.
COMING SOON GUIDELINES EFFECTIVE AS OF MARCH 3, 2020*
* GUIDELINES EFFECTIVE AS OF MARCH 4, 2020 FOR PREMERA BLUE CROSS AND LIFEWISE MEMBERS
AIM CLINICAL APPROPRIATENESS GUIDELINES FOR MOLECULAR TESTING OF SOLID AND HEMATOLOGIC TUMORS AND MALIGNANCIES
The testing addressed in the AIM Clinical Appropriateness Guidelines for Molecular Testing of Solid and Hematologic Tumors and Malignancies includes genetic testing and gene expression profiling of solid and hematologic tumors for the purpose of diagnosis or for information related to treatment selection, prognosis, or recurrence risks.
COMING SOON GUIDELINES EFFECTIVE AS OF DECEMBER 9, 2019
COMING SOON GUIDELINES EFFECTIVE AS OF MARCH 3, 2020*
* GUIDELINES EFFECTIVE AS OF MARCH 4, 2020 FOR PREMERA BLUE CROSS AND LIFEWISE MEMBERS
AIM CLINICAL APPROPRIATENESS GUIDELINES FOR PHARMACOGENETIC TESTING AND GENETIC TESTING FOR THROMBOTIC DISORDERS
The testing addressed in the AIM Clinical Appropriateness Guidelines for Pharmacogenetic Testing and Genetic Testing for Thrombotic Disorders includes genotyping to predict response to certain medications and testing for gene mutations associated with coagulation disorders.
COMING SOON GUIDELINES EFFECTIVE AS OF MARCH 3, 2020*
* GUIDELINES EFFECTIVE AS OF MARCH 4, 2020 FOR PREMERA BLUE CROSS AND LIFEWISE MEMBERS
AIM CLINICAL APPROPRIATENESS GUIDELINES FOR GENETIC TESTING FOR SINGLE-GENE AND MULTIFACTORIAL CONDITIONS
The testing addressed in the AIM Clinical Appropriateness Guidelines for Genetic Testing for Single-Gene and Multifactorial Conditions includes single-gene testing, multigene diagnostic panels, testing for variants associated with multifactorial conditions, chromosomal microarray analysis, and human leukocyte antigen (HLA) histocompatibility testing.
COMING SOON GUIDELINES EFFECTIVE AS OF MARCH 3, 2020*
* GUIDELINES EFFECTIVE AS OF MARCH 4, 2020 FOR PREMERA BLUE CROSS AND LIFEWISE MEMBERS
AIM CLINICAL APPROPRIATENESS GUIDELINES FOR WHOLE EXOME AND WHOLE GENOME SEQUENCING
The testing addressed in the AIM Clinical Appropriateness Guidelines for Whole Exome and Whole Genome Sequencing includes the diagnostic use of whole exome and genome sequencing in the evaluation of rare disease.
COMING SOON GUIDELINES EFFECTIVE AS OF MARCH 3, 2020*
* GUIDELINES EFFECTIVE AS OF MARCH 4, 2020 FOR PREMERA BLUE CROSS AND LIFEWISE MEMBERS
AIM CLINICAL APPROPRIATENESS GUIDELINES FOR GENETIC TESTING FOR REPRODUCTIVE CARRIER SCREENING AND PRENATAL DIAGNOSIS
The testing addressed in the AIM Clinical Appropriateness Guidelines for Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis includes carrier testing for familial mutations and common and ethnic genetic diseases; preimplantation screening and diagnosis; prenatal screening and diagnosis; and testing for recurrent pregnancy loss and infertility.
COMING SOON GUIDELINES EFFECTIVE AS OF MARCH 3, 2020*
* GUIDELINES EFFECTIVE AS OF MARCH 4, 2020 FOR PREMERA BLUE CROSS AND LIFEWISE MEMBERS
Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2019 Informed Medical Decisions, Inc. All rights reserved.
CLINICAL GUIDELINES ACCESS
BY CLICKING ON THE “I ACCEPT” BUTTON BELOW, I ACKNOWLEDGE ACCEPTANCE OF THE FOLLOWING TERMS AND CONDITIONS FOR ACCESS AND USE OF THE CLINICAL GUIDELINES:
AIM Specialty Health has developed proprietary Diagnostic Imaging Utilization Management Clinical Guidelines (together with any updates, referred to collectively as the “Guidelines”). The Guidelines are designed to evaluate and direct the appropriate utilization of high technology diagnostic imaging services. They are based on data from the peer-reviewed scientific literature, from criteria developed by specialty societies and from guidelines adopted by other health care organizations. Access to these Guidelines is being provided for informational purposes only. AIM is under no obligation to update its Guidelines. Therefore, these Guidelines may be out of date.
The Guidelines are protected by copyright of AIM as permitted by and to the full extent of the law. These rights are not released, transferred, or assigned as a result of allowing access. You agree that you do not have any ownership rights to the Guidelines and you are expressly prohibited from selling, assigning, leasing, licensing, reproducing or distributing the Guidelines, unless authorized in writing by AIM.
The Guidelines do not constitute medical advice and/or medical care, and do not guarantee results or outcomes. The Guidelines are not a substitute for the experience and judgment of a physician or other health care professionals. Any clinician seeking to apply or consult the Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The Guidelines do not address coverage, benefit or other plan specific issues.
The Guidelines are provided “as is” without warranty of any kind, either expressed or implied.
AIM disclaims all responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in the Guidelines.